Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 40,000 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $266,580. The trade was a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ian Mortimer also recently made the following trade(s):

• On Monday, December 8th, Ian Mortimer sold 10,830 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $45.73, for a total transaction of $495,255.90.
• On Friday, December 5th, Ian Mortimer sold 14,375 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $45.03, for a total value of $647,306.25.
• On Friday, November 28th, Ian Mortimer sold 97 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $45.01, for a total value of $4,365.97.

Xenon Pharmaceuticals Stock Down 0.7%

XENE opened at $44.49 on Friday. The stock has a market cap of $3.44 billion, a PE ratio of -11.44 and a beta of 1.03. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.60. The business’s fifty day simple moving average is $42.66 and its 200 day simple moving average is $38.30.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.01. During the same quarter in the previous year, the firm posted ($0.81) earnings per share. The business’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Arizona State Retirement System increased its stake in Xenon Pharmaceuticals by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 334 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Xenon Pharmaceuticals by 15.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,964 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 403 shares during the period. Quarry LP increased its stake in shares of Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 500 shares during the period. State of Wyoming grew its stake in shares of Xenon Pharmaceuticals by 112.8% during the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 610 shares in the last quarter. Finally, Farther Finance Advisors LLC acquired a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $25,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on XENE shares. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 7th. JPMorgan Chase & Co. raised their price objective on Xenon Pharmaceuticals from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Wells Fargo & Company raised their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $54.64.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.